Viewing nowCombinationSitagliptin Metformin Duo Tablet 50/1000 mg
Sitagliptin Hydrochloride Hydrate 56.69mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
ShinPoong Pharmaceutical Co., Ltd.

MFDS item code 202300859 · Approved 2023.03.13 · Insurance code 648508210
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication contains sitagliptin and metformin and is used to aid blood glucose control in patients with type 2 diabetes when used alongside dietary regulation and exercise. In other words, it helps to manage blood sugar levels stably, thereby improving diabetes symptoms.
The dose of this drug for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This drug is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this drug is determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no previous history of antidiabetic drug therapy who have difficulty achieving adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose of this drug is 1 tablet of 50/500 mg twice daily. The dose may be increased to 1 tablet of 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this drug (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - The recommended initial dose of this drug for patients who cannot achieve adequate glycemic control with metformin monotherapy is sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's existing metformin dose. - Patients switching to this drug from combination therapy with sitagliptin and metformin may start at their existing doses of sitagliptin and metformin. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this drug is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should take the patient's blood glucose level and existing dose into consideration. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When this drug is administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching to this drug in patients previously treated with another oral antihyperglycemic agent. Any change in treatment for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate [eGFR] ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this drug. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).
This medication contains sitagliptin and metformin and is mainly used for the treatment of type 2 diabetes. During the course of this medication, serious allergic reactions may occur; therefore, if symptoms such as skin rash, difficulty breathing, or swelling of the face or neck occur, it is essential to cease taking the medication immediately and consult a healthcare professional. Severe side effects like pancreatitis, which is inflammation of the pancreas, have been reported; if symptoms such as abdominal pain, nausea, or vomiting occur, inform your doctor immediately. Patients with severely impaired kidney function, acute heart conditions, or serious infections should not use this medication, and the decision to administer it should be based on kidney function test results. This medication may cause a rare but fatal metabolic complication known as lactic acidosis; thus, if sudden fatigue, muscle pain, difficulty breathing, or abdominal pain occurs, cease treatment immediately and visit a hospital. Excessive alcohol consumption increases the risk of lactic acidosis; therefore, it is crucial to avoid drinking alcohol while taking this medication. If undergoing surgery or in a state of severe infection or dehydration, temporarily discontinue this medication and resume once recovery is achieved and kidney function returns to normal. When taken alongside other medications with strong blood sugar-lowering effects, the risk of hypoglycemia may increase; hence, regular monitoring of blood sugar levels and awareness of hypoglycemia symptoms are necessary. Particularly elderly patients or those with poor nutritional status have a higher risk of hypoglycemia or lactic acidosis; thus, regular kidney function and blood tests should be conducted. It is advised not to use this medication during pregnancy, breastfeeding, or for children under 18 years of age. During the use of this medication, regular checks on blood sugar, kidney function, and vitamin B12 levels should be conducted to continuously monitor health status. In cases of medication overdose, visit a medical facility immediately for appropriate treatment, as some components can be removed through dialysis.
Anaphylaxis, angioedema, Stevens-Johnson syndrome, acute pancreatitis, lactic acidosis, hypoglycemia, diarrhea, upper respiratory tract infection, headache, nausea, vomiting, abdominal pain, nasopharyngitis, peripheral edema, severe and disability-associated arthralgia, blistering dermatitis, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, rhabdomyolysis, dermatitis, anorexia, weight loss, dyspnea, unstable angina, dizziness, acute renal failure, decreased appetite, gastrointestinal disorders, itching
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent air or moisture ingress, preferably at room temperature between 1 and 30 degrees Celsius. This helps maintain the efficacy of the medication and prevents deterioration.
Oval, reddish-brown film-coated tablet
Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.69mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
ShinPoong Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.